Objective: Overweight and obesity is a risk factor for hypertension. Malignant hypertension (MHT) is the most severe form of hypertension, and thrombotic microangiopathy (TMA), one of its complications, has been linked to significant renal outcomes. However, the impact of overweight and obesity on renal prognosis in MHT patients with TMA is not well understood.Methods: This was a prospective cohort enrolled 288 MHT patients with renal TMA from 2008 to 2023. The clinical and histopathological characteristics were recorded based on body mass index (BMI, < 25 and ≥ 25 kg/m2). The outcome was the incidence of kidney failure. The associations of BMI with kidney failure were examined in logistic regression models.Results: Among 288 patients, 180 (62.5%) progressed to kidney failure, including 113 (68.5%) patients with BMI < 25 kg/m2. Participants with obesity had higher levels of hemoglobin, estimated glomerular filtration rate and C3, but lower levels of serum creatinine and IgA nephropathy. BMI ≥ 25 kg/m2 was associated with a better outcome of kidney failure in MHT patients with TMA (odd ratios [ORs]: 0.49 [95% confidence interval (CI): 0.27–0.91], p = 0.025). Male, uric acid, onion skin lesions, and global sclerosis ratio were correlated with higher risk of kidney failure; serum albumin and treatment with renin–angiotensin system blockers were related to lower risk of kidney failure.Conclusions: In MHT patients with renal TMA, normal‐weight rather than overweight was found to associate with a worse renal prognosis. Management efforts for MHT may be directed toward controlling body weight within a reasonable range for patients.
Background: Malignant hypertension (mHTN) is an acute form of hypertension with multiorgan damage, including renal impairment. Renal cortical thickness (RCT) by ultrasonography is associated with renal function in kidney disease. However, the relationship between RCT and renal dysfunction in mHTN is not yet fully understood. Design: A cohort study. Setting: This was a study conducted between January 2008 and June 2023 at the First Affiliated Hospital of Sun Yat-sen University. Participants: A total of 292 mHTN patients with thrombotic microangiopathy (TMA) who underwent renal biopsy were included in the study. Primary outcomes and measures: Patient characteristics for RCT were examined using linear regression. The association between RCT and an increase in estimated glomerular filtration rate (eGFR) of ≥15% was analysed by Cox regression. RCT was analysed in two groups classified by median RCT. Results: Overall, patients with larger RCT exhibited a lower global sclerosis ratio and a lower proportion of intravascular thrombosis. RCT was strongly positively correlated with mean kidney length (coefficient B 1.018; 95% CI 0.638 to 1.397; p <0.001), body mass index (BMI) (coefficient B 0.146; 95% CI 0.075 to 0.217; p <0.001) and negatively related to intravascular thrombosis (coefficient B −1.314; 95% CI −2.060 to −0.567; p =0.001) and tubular atrophy/interstitial fibrosis ratio (coefficient B −0.880; 95% CI −1.569 to −0.192; p =0.012). Moreover, larger RCTs had a better renal function improvement of ≥15% increase in eGFR in patients with mHTN with TMA (HR 1.745; 95% CI 1.012 to 3.009; p =0.045). Conclusions: Smaller RCTs were correlated with a decline in renal function and deterioration of renal pathology. Furthermore, larger RCTs showed a better renal function improvement of ≥15% increase in eGFR in mHTN patients with TMA. RCT may be a predictive factor for renal damage in mHTN.
Background: Thrombotic microangiopathy (TMA) is a major complication of malignant hypertension (mHTN). Abnormal complement activation has been recognized as a key determinant of TMA, but less is known about the prognostic significance of complement abnormality in patients with mHTN-associated TMA. Methods: A prospective cohort study was performed in patients with mHTN. All participants had concomitant TMA proven by kidney biopsy after admission between 2008 and 2023, and were divided into normal and abnormal complement groups based on serum C3 and C4 levels. Cox regression models were used to identify risk factors for renal prognosis. Results: A total of 189 mHTN patients with TMA were enrolled in the current study, including 161 (85.2%) patients with normal complement levels and 28 (14.8%) patients with abnormal complement levels. Compared to the normal complement group, patients in the abnormal complement group had lower levels of BMI, hemoglobin, and platelet counts, and more intravascular erythrocyte fragments (21.4% vs 7.5%, P = .02). Notably, a substantial glomerular deposition of C3c and C5b-9 was observed in the abnormal complement group, indicating complement activation in vivo. Importantly, abnormal complement levels were independently associated with worse renal function recovery [hazard ratio (HR), 0.368; 95% CI, 0.140–0.970; P = .043]. In addition, the glomerular sclerosis ratio (HR, 0.971; 95% CI, 0.953–0.989; P = .002) remained an independent predictor of poor renal outcomes. Conclusions: Patients with abnormal complement levels have worse renal prognosis, suggesting that complement abnormality predisposes to the progression of mHTN-associated TMA disease.
Introduction: Malignant hypertension (mHTN) is a hypertensive emergency. Thrombotic microangiopathy (TMA) is a widespread complication of mHTN. Few studies have evaluated whether glomerular hematuria provides prognostic information for renal dysfunction in patients with mHTN-associated TMA. Methods: This observational cohort study included 292 patients with mHTN-associated TMA based on renal biopsy. Propensity-score matching (PSM) analysis was conducted to adjust for clinical characteristics in a comparison between with and without glomerular hematuria. Cox regression was employed to identify risk factors for renal prognosis. Results: A total of 70 patients with glomerular hematuria were compared to 222 patients with non-glomerular hematuria. After PSM, 67 pairs of patients with mHTN-associated TMA were matched. Patients with glomerular hematuria exhibited lower serum albumin levels, higher 24-h proteinuria, and a higher prevalence of glomerular sclerosis than those with non-glomerular hematuria. Glomerular hematuria was independently associated with deteriorated renal function compared with non-glomerular hematuria (HR: 0.51; 95% CI: 0.29–0.89, p = 0.019). This association remained significant after PSM (HR: 0.51; 95% CI: 0.28–0.91, p = 0.022). Additionally, glomerular hematuria was independently associated with renal replacement therapy (RRT) (HR: 3.14; 95% CI: 2.06–5.66, p < 0.001). This difference remained significant after PSM comparison (HR: 2.41; 95% CI: 1.34–4.33, p = 0.003). Furthermore, despite intensive blood pressure control, patients with glomerular hematuria experienced a higher incidence of RRT and a poorer recovery in renal function, specifically a 25% reduction of creatinine levels, compared to patients with non-glomerular hematuria. Conclusion: Glomerular hematuria is significantly associated with an increased risk of adverse renal outcomes in patients with mHTN-associated TMA.
Malignant hypertension (mHTN) is the most severe form of hypertension. Thrombotic microangiopathy (TMA) serves as both a complication of mHTN and a contributor to its progression by exacerbating renal damage. Proteinuria is a common manifestation of mHTN. However, the impact of proteinuria on renal prognosis in mHTN patients with TMA is unclear. This observational cohort study included 276 mHTN-associated TMA patients based on renal biopsy from 2008 to 2023. Demographic characteristics, laboratory results, and histopathological findings were recorded and compared between the mild (< 1 g / 24 h) and significant (≥ 1 g / 24 h) proteinuria groups. Propensity score matching (PSM) was used to adjust for baseline differences. Cox regression model was employed to evaluate risk factors associated with renal prognosis. Among the 276 patients included in the study, 185 (67.0%) had significant proteinuria, while 91 (33.0%) had mild proteinuria at baseline. After PSM, 83 pairs of patients with mHTN-associated TMA were matched. Patients with significant proteinuria exhibited lower serum albumin, and higher ratio of global sclerosis compared to patients with mild proteinuria. Moreover, mHTN-associated TMA with significant proteinuria was independently associated with receiving renal replacement therapy (RRT) (adjusted hazard ratio (aHR), 1.30; 95% confidence interval (CI), 1.16–1.46; P < 0.001) compared with mild proteinuria. This association remained significant after PSM (aHR, 1.29; 95% CI, 1.13–1.47; P < 0.001). Furthermore, mHTN-associated TMA patients with significant proteinuria had a lower incidence of renal function recovery with a reduction in creatinine levels than in patients with mild proteinuria in the absence of intensive blood pressure control. In mHTN-associated TMA patients, the presence of significant proteinuria serves as a strong predictor of poor renal outcome. Not applicable.